{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:03:45Z","timestamp":1747181025500,"version":"3.40.5"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"35","license":[{"start":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T00:00:00Z","timestamp":1662076800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,9,2]]},"abstract":"<jats:p>Real-life data on the HCV treatment with direct-acting agents in patients with decompensated cirrhosis are scarce. Study to investigate the effectiveness and safety of sofosbuvir-containing regimens in a prospective cohort of patients with HCV decompensated cirrhosis. A total of 150 patients were enrolled (64% male, 84% genotype 1 with a mean age of 61\u2009\u00b1\u20099 years). The median MELD was 12, and 79% were Child-PughB. Most patients were treated with sofosbuvir and daclatasvir (98%) with ribavirin in 27%. The overall intention to treat SVR12 was 91% (137\/150). The most frequent adverse event was anemia (17%), 73% associated with ribavirin. Twenty-one (14%) patients experienced renal dysfunction, 81% AKI I, and 1 discontinued treatment. Thirty-five (23%) patients presented at least 1 infectious episode, mainly respiratory tract infection (29%). Thirty-three patients (22%) had at least 1 episode of cirrhosis decompensation throughout treatment, particularly worsening of previous ascites in 19%. Nine patients died, and among those, 7 patients died from sepsis. The probability of decompensation in 28, 90 and 180 days was 4%, 19% and 25%. During treatment, infection (OR 2.24; 95 CI 1.09\u20134.61; <jats:italic toggle=\"yes\">P<\/jats:italic> = .03) was a predictor of cirrhosis decompensation, and baseline MELD and CHILD \u2265 B8 were both associated with infection. In decompensated cirrhosis, the overall virological response was high with mild adverse events. However, this population had a high frequency of liver-associated decompensation and infections.<\/jats:p>","DOI":"10.1097\/md.0000000000030097","type":"journal-article","created":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T16:24:38Z","timestamp":1662135878000},"page":"e30097","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Results of interferon-free treatment for HCV-infected patients with decompensated cirrhosis from a Brazilian real-life cohort"],"prefix":"10.1097","volume":"101","author":[{"given":"L\u00edvia","family":"Victor","sequence":"first","affiliation":[{"name":"School of Medicine, Internal Medicine Department, Hepatology Division, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil"},{"name":"Gastroenterology and Hepatology Unit, Bonsucesso Federal Hospital, Rio de Janeiro, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renata","family":"Perez","sequence":"additional","affiliation":[{"name":"School of Medicine, Internal Medicine Department, Hepatology Division, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fl\u00e1via","family":"Fernandes","sequence":"additional","affiliation":[{"name":"Gastroenterology and Hepatology Unit, Bonsucesso Federal Hospital, Rio de Janeiro, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliana","family":"Piedade","sequence":"additional","affiliation":[{"name":"Gastroenterology and Hepatology Unit, Bonsucesso Federal Hospital, Rio de Janeiro, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristiane A.","family":"Villela-Nogueira","sequence":"additional","affiliation":[{"name":"School of Medicine, Internal Medicine Department, Hepatology Division, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2768-9605","authenticated-orcid":false,"given":"Gustavo","family":"Pereira","sequence":"additional","affiliation":[{"name":"Gastroenterology and Hepatology Unit, Bonsucesso Federal Hospital, Rio de Janeiro, Brazil"},{"name":"School of Medicine, Est\u00e1cio de S\u00e1 University, Rio de Janeiro, Brazil."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"issue":"suppl 1","key":"R1-20250504","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.jhep.2014.07.012","article-title":"Natural history of hepatitis C","volume":"61","author":"Westbrook","year":"2014","journal-title":"J Hepatol"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.bjid.2019.04.010","article-title":"Hepatitis C disease burden and strategies for elimination by 2030 in Brazil. A mathematical modeling approach","volume":"23","author":"Benzaken","year":"2019","journal-title":"Braz J Infect Dis"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1080\/13543784.2016.1225036","article-title":"The therapeutic potential of new investigational hepatitis C virus translation inhibitors","volume":"25","author":"Borgia","year":"2016","journal-title":"Expert Opin Investig Drugs"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1517\/17460441.2015.1094051","article-title":"The discovery of sofosbuvir: a revolution for therapy of chronic hepatitis C","volume":"10","author":"Gentile","year":"2015","journal-title":"Expert Opin Drug Discov"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1517\/13543784.2016.1161023","article-title":"Investigational direct-acting antivirals in hepatitis C treatment: the latest drugs in clinical development","volume":"25","author":"Gentile","year":"2016","journal-title":"Expert Opin Investig Drugs"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S1473-3099(16)00052-9","article-title":"Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial","volume":"16","author":"Manns","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/hep.28446","article-title":"Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence","volume":"63","author":"Poordad","year":"2016","journal-title":"Hepatology"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/S2468-1253(16)30009-7","article-title":"Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial","volume":"1","author":"Younossi","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.jhep.2016.01.029","article-title":"Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis","volume":"64","author":"Foster","year":"2016","journal-title":"J Hepatol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jceh.2017.11.011","article-title":"Impact of direct acting antiviral drugs in treatment naive HCV cirrhosis on fibrosis and severity of liver disease: a real life experience from a tertiary care center of North India","volume":"8","author":"Garg","year":"2018","journal-title":"J Clin Exp Hepatol"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/apt.14404","article-title":"Sofosbuvir and daclatasvir therapy in patients with hepatitis C-related advanced decompensated liver disease (MELD >\/= 15)","volume":"47","author":"McCaughan","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s12072-018-9914-6","article-title":"Treatment with direct-acting antivirals improves the clinical outcome in patients with HCV-related decompensated cirrhosis: results from an Italian real-life cohort (Liver Network Activity-LINA cohort)","volume":"13","author":"Gentile","year":"2019","journal-title":"Hepatol Int"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13027-017-0158-1","article-title":"Outcomes after sofosbuvir-containing regimens for hepatitis C virus in patients with decompensated cirrhosis: a real-world study","volume":"12","author":"Ji","year":"2017","journal-title":"Infect Agent Cancer"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/lt.24324","article-title":"Safety and efficacy of simeprevir plus sofosbuvir with or without ribavirin in patients with decompensated genotype 1 hepatitis C cirrhosis","volume":"22","author":"Modi","year":"2016","journal-title":"Liver Transpl"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1111\/jvh.13148","article-title":"BARCOS (Brazilian Argentine Hepatitis C Collaborative Observational Study): effectiveness and clinical outcomes of HCV treatment with daclatasvir and sofosbuvir with or without ribavirin","volume":"26","author":"Ridruejo","year":"2019","journal-title":"J Viral Hepat"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jinf.2018.04.001","article-title":"Real life efficacy of ledipasvir\/sofosbuvir in hepatitis C genotype 4-infected patients with advanced liver fibrosis and decompensated cirrhosis","volume":"76","author":"Sanai","year":"2018","journal-title":"J Infect"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1002\/hep.27922","article-title":"Safety and efficacy of simeprevir\/sofosbuvir in hepatitis C-infected patients with compensated and decompensated cirrhosis","volume":"62","author":"Saxena","year":"2015","journal-title":"Hepatology"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jceh.2018.02.009","article-title":"Results of sofosbuvir plus ribavirin in patients with hepatitis C related decompensated cirrhosis","volume":"9","author":"Tmu","year":"2019","journal-title":"J Clin Exp Hepatol"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s12879-022-07076-0","article-title":"Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis","volume":"22","author":"Pageaux","year":"2022","journal-title":"BMC Infect Dis"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.jhep.2013.04.035","article-title":"Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890","volume":"59","author":"Hezode","year":"2013","journal-title":"J Hepatol"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s10620-014-3422-x","article-title":"Hepatic decompensation likely attributable to simeprevir in patients with advanced cirrhosis","volume":"60","author":"Stine","year":"2015","journal-title":"Dig Dis Sci"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/ajg.2015.218","article-title":"Treatment of chronic HCV with sofosbuvir and simeprevir in patients with cirrhosis and contraindications to interferon and\/or ribavirin","volume":"110","author":"Shiffman","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1053\/jhep.2001.22172","article-title":"A model to predict survival in patients with end-stage liver disease","volume":"33","author":"Kamath","year":"2001","journal-title":"Hepatology"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/bjs.1800600817","article-title":"Transection of the oesophagus for bleeding oesophageal varices","volume":"60","author":"Pugh","year":"1973","journal-title":"Br J Surg"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/hepr.13303","article-title":"Rescue therapy for chronic hepatitis C virus infection after repeated treatment failures: impact on disease progression and risk of hepatocellular carcinoma","volume":"49","author":"Hanafy","year":"2019","journal-title":"Hepatol Res"},{"key":"R26-20250504","first-page":"143","article-title":"Hepatitis C virus: efficacy of new DAAs regimens","volume":"20","author":"Mohamed","year":"2020","journal-title":"Infect Disord Drug Targets"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1007\/s11096-017-0552-1","article-title":"Adverse effects of direct acting antiviral-based regimens in chronic hepatitis C patients: a Brazilian experience","volume":"39","author":"Medeiros","year":"2017","journal-title":"Int J Clin Pharm"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1002\/jmv.24816","article-title":"Ombitasvir\/paritaprevir\/ritonavir\/dasabuvir +\/- ribavirin is safe and effective in HCV-infected patients in a real-life cohort from Latin America","volume":"89","author":"Mendizabal","year":"2017","journal-title":"J Med Virol"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.transproceed.2018.02.001","article-title":"Daclatasvir and sofosbuvir with or without Ribavirin in liver transplant recipients: a single-center real-world study","volume":"50","author":"Mucenic","year":"2018","journal-title":"Transplant Proc"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.aohep.2019.08.001","article-title":"Direct antiviral therapy for treatment of hepatitis C: a real-world study from Brazil","volume":"18","author":"Lobato","year":"2019","journal-title":"Ann Hepatol"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/jvh.12645","article-title":"Simeprevir, daclatasvir and sofosbuvir for hepatitis C virus-infected patients with decompensated liver disease","volume":"24","author":"Lawitz","year":"2017","journal-title":"J Viral Hepat"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"e270421186971","DOI":"10.2174\/1871526520666201019122205","article-title":"Treatment of hepatitis C cirrhotic patients with directly acting antivirals: a multicenter study","volume":"21","author":"Elfert","year":"2021","journal-title":"Infect Disord Drug Targets"},{"issue":"3 pt B","key":"R33-20250504","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3851\/IMP2606","article-title":"Genetic diversity of HCV in Brazil","volume":"18","author":"Lampe","year":"2013","journal-title":"Antivir Ther"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jhep.2005.10.013","article-title":"Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies","volume":"44","author":"D\u2019Amico","year":"2006","journal-title":"J Hepatol"},{"issue":"suppl 1","key":"R35-20250504","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s12072-017-9808-z","article-title":"New concepts on the clinical course and stratification of compensated and decompensated cirrhosis","volume":"12","author":"D\u2019Amico","year":"2018","journal-title":"Hepatol Int"},{"key":"R36-20250504","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jhep.2004.10.019","article-title":"Patients with acute on chronic liver failure display \u201csepsis-like\u201d immune paralysis","volume":"42","author":"Wasmuth","year":"2005","journal-title":"J Hepatol"},{"key":"R37-20250504","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hep.20632","article-title":"Bacterial translocation (BT) in cirrhosis","volume":"41","author":"Wiest","year":"2005","journal-title":"Hepatology"},{"key":"R38-20250504","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1053\/j.gastro.2010.06.019","article-title":"Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis","volume":"139","author":"Arvaniti","year":"2010","journal-title":"Gastroenterology"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000030097","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T04:35:47Z","timestamp":1746333347000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000030097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,2]]},"references-count":38,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000030097","relation":{},"ISSN":["1536-5964"],"issn-type":[{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2022,9,2]]}}}